Hunan Jingfeng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
October 27, 2021 at 04:54 am EDT
Share
Hunan Jingfeng Pharmaceutical Co.,Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 559.77 million compared to CNY 936.5 million a year ago. Revenue was CNY 559.77 million compared to CNY 936.5 million a year ago. Net income was CNY 14.66 million compared to CNY 75.82 million a year ago. Basic earnings per share from continuing operations was CNY 0.0167 compared to CNY 0.0862 a year ago. Diluted earnings per share from continuing operations was CNY 0.0167 compared to CNY 0.0862 a year ago.
Hunan Jingfeng Pharmaceutical Co.,Ltd., formerly Hunan Tianyi Science and Technology Co., Ltd, is a China-based company principally engaged in the research, development, manufacture and sale of chemical drugs, biochemical drugs and traditional Chinese patent drugs. The Company's main products includes cardio and cerebrovascular drugs, antihypertensive and hypolipidemic drugs, orthopedic drugs, anti-tumor products, endocrine drugs, digestive system drugs, antiviral drugs and anti-infective drugs, among others. The Company is also involved in commodity import and export trading, business management and consulting, as well as medical technology consulting business. The Company distributes its products in the domestic market.